Form 10-K Corvus Pharmaceuticals, For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Corvus Pharmaceuticals (CRVS) PT Lowered to $7 at Oppenheimer
March 20, 2024 4:38 AM EDTOppenheimer analyst Jeff Jones lowered the price target on Corvus Pharmaceuticals (NASDAQ: CRVS) to $7.00 (from $8.00) while maintaining a Outperform rating.
The analyst comments "On Tuesday CRVS announced 4Q and full-year results, highlighting a somewhat narrowed plan for lead candidate soquelitinib. Management is... More
